Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study

Rheumatology (United Kingdom)

Volumn 56, Issue 9, 2017, Pages 1618-1626

  Rose, Thomas ^a   Grützkau, Andreas ^b   Klotsche, Jens ^b   Enghard, Philipp ^b   Flechsig, Alexandra ^a   Keller, Johannes ^a   Riemekasten, Gabriela ^c   Radbruch, Andreas ^b   Burmester, Gerd Rüdiger ^a   Dörner, Thomas ^a   Hiepe, Falk ^a   Biesen, Robert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Rheumatism Research Center Berlin   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Autoimmunity; Biomarker; Interferon; IP 10; Longitudinal; Sialic acid binding Ig like lectin 1; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON INDUCIBLE PROTEIN 10; SIALOADHESIN; CXCL10 PROTEIN, HUMAN; SIGLEC1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BENCHMARKING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FARR RADIOIMMUNOASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LABORATORY TEST; LONGITUDINAL STUDY; MALE; MEASUREMENT ACCURACY; MONOCYTE; NUCLEOSOME; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SENSITIVITY AND SPECIFICITY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; YOUDEN INDEX; BLOOD; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; BENCHMARKING; BIOMARKERS; CHEMOKINE CXCL10; FEMALE; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SIALIC ACID BINDING IG-LIKE LECTIN 1; YOUNG ADULT;

EID: 85030425661     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex220     Document Type: Article

References (32)

1. Mosca M, Tani C, Aringer M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74
2. Bauer JW, Petri M, Batliwalla FM et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009;60:3098-107
3. Kong KO, Tan AW, Thong BYH et al. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 2009;156:134-40
4. Biesen R, Dähnrich C, Rosemann A et al. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res Ther 2011;13:R26
5. Kao AH, Navratil JS, Ruffing MJ et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 2010;62:837-44
6. Hooks JJ, Moutsopoulos HM, Geis SA et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8
7. Kirou KA, Lee C, George S et al. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-503
8. Feng X, Wu H, Grossman JM et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62
9. Rose T, Grutzkau A, Hirseland H et al. IFN and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 2013;72:1639-45
10. Bengtsson AA, Sturfelt G, Truedsson L et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71
11. Landolt-Marticorena C, Bonventi G, Lubovich A et al. Lack of association between the interferon-a signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009;68:1440-6
12. Petri M, Singh S, Tesfasyone H et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009;18:980-9
13. Hillebrand JJG, Moens HB, Mulder AHL. Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE. Lupus 2013;22:1169-73
14. Biesen R, Demir C, Barkhudarova F et al. Sialic acidbinding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008;58:1136
15. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7
16. Isenberg DA, Rahman A, Allen E et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005;44:902-6
17. Cresswell L, Yee C-S, Farewell V et al. Numerical scoring for the Classic BILAG index. Rheumatology 2009;48:1548-52
18. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91
19. Gordon C. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42:1372-9
20. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J 2005;47:458-72
21. Yee C-S, Isenberg DA, Prabu A et al. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis 2008;67:873-6
22. Klotsche J, Ferger D, Pieper L, Rehm J, Wittchen H-U. A novel nonparametric approach for estimating cut-offs in continuous risk indicators with application to diabetes epidemiology. BMC Med Res Methodol 2009;9:63
23. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000;19:1141-64
24. Li T, Prokopec SD, Morrison S et al. Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. Rheumatology 2015;54:449-57
25. Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CGM. Measurement of increases in anti-double-stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum 1990;33:634-43
26. ter Borg EJ, Horst G, Limburg PC, Kallenberg CG. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol 1990;82:21-6
27. Bootsma H, Spronk P, Borg E et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation. Ann Rheum Dis 1997;56:661-6
28. Hui-Yuen JS, Reddy A, Taylor J et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol 2015;42:2288-95
29. Vollenhoven RF, van, Petri MA, Cervera R, Roth DA et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9
30. Alexander T, Sarfert R, Klotsche J et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015;74:1474-8
31. Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev 2012;12:97-106
32. Kikuchi-Taura A, Yura A, Tsuji S et al. Monocyte CD64 expression as a novel biomarker for the disease activity of systemic lupus erythematosus. Lupus 2015;24:1076-80